The Accellacare Site Network's feasibility and central process management enables faster study start-up and its dedicated patient engagement team drives identification and recruitment of suitable patients, using an extensive database of patients and targeted campaigns, resulting in higher recruitment levels per site.
Accellacare extends across the globe with 82 active research sites in six countries with expertise in a wide range of therapeutic areas. It has relationships with 275 Principal Investigators connecting it to 8 million+ patients.
82active research sites in 6 countries
Using a finely tuned site feasibility approach and central process management, including budgeting and contracting, Accellacare achieves faster study start-up. This means patient recruitment can start earlier to achieve important early milestones.
Accellacare’s dedicated patient engagement team drive the identification and recruitment of suitable patients, using an extensive database of patients and targeted campaigns on digital channels, resulting in higher recruitment levels per site.
Focus on quality
Consistent, centralised training programs in quality assurance and compliance ensures that we are always inspection ready. High quality training, tools, centralised SOPs and Core Operating Guidelines (COGs) as well as oversight across all sites has resulted in positive outcomes for our clients. Accellacare has had 15 regulatory audits in the past five years with no findings.
Delivery on the ground
Various models available including embedded research personnel managing clinical research within a healthcare institute or physician’s office
- Supporting specific studies or all research
- Providing on demand patient recruiters, study coordinators, data entry staff
- Standardised technology, processes and IT management
- Research study sourcing, feasibility and EMR query tools
- Quality Management System
- Budget and contract negotiation
- Human resource management and training
The Accellacare site network includes 82 sites spanning the US, UK, Spain, Bulgaria, Russia, and South Africa.